Skip to content Skip to footer
Subscribe Now
PharmaShots Interview PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100
VIEWPOINTS

PharmaShots Interview: PolyPid’s Dikla Czaczkes Akselbrad Shares Insights on the P-III (SHIELD I) Trial of D-PLEX100

In an interview with PharmaShots, Dikla Czaczkes Akselbrad, Executive Vice President, Chief Financial Officer at PolyPid shares her views on Q3’21 financial results & P-III (SHIELD I) trial of D-PLEX100 in patients with incisional SSIs in post-abdominal surgeryShots:The P-III (SHIELD I) trial evaluates the efficacy and safety of D-PLEX100 in ~500 patients with incisional SSIs in post-abdominal surgery. The trial continues to enroll…
February 16, 2022

Read more

VIEWPOINTS

PharmaShots Interview: 180 Life Sciences’ Dr. Jim Woody Shares Insight on Repurposing Anti-TNF to Meet Unmet Needs in Pain and Inflammation

In an interview with PharmaShots, Dr. Jim Woody, MD, Ph.D., Chief Executive Officer at 180 Life Sciences shared his insights on the Phase 2b study of anti-TNF for the treatment of the early Dupuytren's disease.Shots:180 Life Sciences used anti-TNF to treat early Dupuytren’s disease and the Phase 2b study is complete.Additional programs using anti-TNF soon to…
February 15, 2022

Read more

PharmaShots Interview Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine
VIEWPOINTS

PharmaShots Interview: Myriad Genetics’ Todd Cohen Shares Insights on the Trends in Prostate Cancer and Precision Medicine

In an interview with PharmaShots, Todd Cohen, MD, Vice President of Medical Affairs/Medical Director of Urology at Myriad Genetics shares his views on the precision medicine and prognostic tests for Prostate CancerShots:The company reported the importance of precision medicine and prognostic tests that can help to determine cancer & enables personalized treatment paths. The company highlights the ability of genetic…
February 9, 2022

Read more

Viewpoints_Philip M. Brown
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip M. Brown Shares Insights on the Clinical Data of Tapinarof Published in NEJM

In an interview with PharmaShots, Philip M. Brown, MD, JD, Chief Medical Officer at Dermavant shares his views on the P-III (PSOARING 1 & 2) trials of tapinarof for the treatment of Plaque PsoriasisShots:The P-III (PSOARING 1 & 2) trials evaluate the efficacy and safety of tapinarof (1%, qd) vs vehicle-controlled cream in a ratio (2:1) in 1025 patients aged…
February 8, 2022

Read more

Viewpoints_Thomas C. Corbridge
VIEWPOINTS

PharmaShots Interview: GSK’s Thomas C. Corbridge Shares Insights on the New Survey Data for Severe Eosinophilic Asthma Patients

In an interview with PharmaShots, Thomas C. Corbridge, US Senior Medical Lead at GSK shares his views on the new survey and demonstrated dissatisfaction with the asthma treatment paradigmShots:The survey was commissioned by GSK and conducted by The Harris Poll in 100 patients aged ≥18yrs. showed that a majority of SEA patients and physicians are concerned about the current state…
January 18, 2022

Read more

PharmaShots Interview Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine
VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, Medical Officer at Medicago shares his views on the P-III study of plant-based COVID-19 vaccine in combination with GSK’s pandemic adjuvant for the treatment of COVID-19 Shots:The company reported efficacy and safety results from the P-III study of Medicago’s plant-based COVID-19 vaccine candidate + GSK’s pandemic adjuvant in ~24,000 adults aged ≥18yrs. across Canada, US, UK,…
January 12, 2022

Read more

PharmaShots Interview Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases
VIEWPOINTS

PharmaShots Interview: Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases

In an interview with PharmaShots, Martina Flammer, Chief Medical Officer at Insmed share her views on the R&D continuum to develop new drugs for rare diseases and also highlights its business pillarsShots:The idea of the continuum is that all department works together to develop the drugs which will be helpful not only for the company but for patients tooIn…
January 11, 2022

Read more

PharmaShots Interview Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology
VIEWPOINTS

PharmaShots Interview: Janssen’s Alyssa Johnsen Shares Insights on the New Clinical data of Tremfya (guselkumab) Presented at ACR 2021 and Published in Arthritis & Rheumatology

In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & RheumatologyShots:The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
January 4, 2022

Read more

PharmaShots Interview Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines
VIEWPOINTS

PharmaShots Interview: Alto Neuroscience’s Dr. Amit Etkin Shares Insights on the Future of Psychiatric Medicines

In an interview with PharmaShots, Dr. Amit Etkin, CEO and Founder of Alto Neuroscience shared his views on its clinical stage pipeline in the emerging hot precision psychiatry space. He also put his views on the funding received by the company for the development of its pipeline.Shots:Using precision psychiatry, the company’s human data R&D platform identifies brain biomarkers…
January 3, 2022

Read more

Viewpoints_Joe Eazor
VIEWPOINTS

PharmaShots Interview: Clario’s Joe Eazor Shares Insight on the Clinical Trial Innovation and Evidence

In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidenceERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement & to generate the clinical evidence, empower the patients &  transform their lives by providing better evidenceClario combines Bioclinica's expertise in imaging,…
December 30, 2021

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]